Diiodotyrosine

Other Names

(2S)-2-Amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid(R)-2-Amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid(S)-2-Amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid2-Amino-3-(4-hydroxy-3,5-diiodo-phenyl)-propionic acid2-Amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid3,5-Diiodo-2-tyrosine3,5-Diiodo-4-hydroxy-beta-phenylalanine3,5-Diiodo-DL-tyrosine3,5-Diiodo-L-tyrosine3,5-Diiodo-tyrosine3,5-Diiodotyrosine3,5-Diiodotyrosine dihydrate3,5-L-DiiodotyrosineAcid, IodogorgoicApothyrinD-DiiodotyrosineDITDitirinDL-DiiodotyrosineIodoglobinIodogorgoic acidJodgorgonL-3,5-DiiodotyrosineL-DiiodotyrosineL-Tyrosine, 3,5-diiodo-NSC 4143Tyrosine, 3,5-diiodo-

Synopsis

Diiodotyrosine (DIT): A Comprehensive Reference

1. Identity and Chemical Characterization

1.1 Names and Nomenclature

Diiodotyrosine (abbreviated DIT) is most precisely named 3,5-diiodo-L-tyrosine, indicating that both iodine atoms are attached at the 3 and 5 positions of the phenolic ring of the amino acid L-tyrosine. DIT is a precursor in the production of thyroid hormone, and results from the iodization of monoiodotyrosine at the other meta-position on the phenol ring. The compound carries a number of synonyms recognized in the chemical and pharmaceutical literature, including iodogorgonic acid, iodogorgic acid, Agontan, Flaianina, Cemiod, and the research designations NSC-208959 and NSC-97936, as well as the pharmaceutical trade names ditirin and iodoglobin. Additional documented synonyms include Jodgorgon and the chemical descriptor H-DL-Tyr(3,5-DiI)-OH. Its CAS registry number is 66-02-4 and its molecular weight is approximately 432.98 g/mol. The synonyms of this drug are ditirin, iodoglobin, and others.

1.2 Structure and Chemical Properties

DIT is a halogenated amino acid derivative — specifically, an iodinated phenolic compound. Thyroid hormones are derived from the amino acid tyrosine and are synthesized through sequential iodination of the tyrosine phenol rings; iodine is added to the phenol ring meta-positions, resulting in diiodotyrosine when two sites are iodinated. The compound retains the full alpha-amino acid backbone of tyrosine (an amino group and a carboxylic acid group on the side chain carbon adjacent to the ring) but bears two iodine atoms on the aromatic ring, giving it considerably greater molecular mass and altered electronic properties relative to its parent amino acid.

1.3 Natural Sources and Occurrence

DIT is an endogenous intermediate formed within the thyroid glands of all vertebrates during thyroid hormone biosynthesis. It does not accumulate in significant free form under normal physiological conditions because the enzyme iodotyrosine deiodinase (IYD) rapidly recycles it within the thyroid. The expression of iodotyrosine deiodinase (IYD) in the thyroid gland ensures efficient recycling of iodine from the byproducts of thyroid hormone biosynthesis: 3′-monoiodotyrosine and 3′,5′-diiodotyrosine.

In the external environment, DIT and structurally related iodinated tyrosines are found in certain marine organisms with high iodine-concentrating capacity. «Iodogorgoric acid» (3,5-diiodotyrosine) was first isolated over 100 years ago from the marine gorgonian Gorgonia cavolinii. Marine macroalgae — particularly brown seaweeds (kelp, Laminaria species, Fucus vesiculosus, Ascophyllum nodosum, and related species) — are among the richest natural external sources of iodinated compounds including DIT. Seafood, iodized salt, and sea vegetables such as kelp are high in iodine, and around 200 species of seaweed are being harvested commercially. The compound has been described as "a source of kelp iodine" in the context of its natural occurrence in kelp-derived preparations. SMC247 (3,5-diiodotyrosine), described as a source of kelp iodine, could strongly bind APOBEC3B (K_D = 65 nM) and effectively inhibit its deaminase activity (IC₅₀ = 1.69 µM) in laboratory studies.

1.4 Common Forms and Preparations

DIT is available as a pure synthetic chemical compound for research purposes, synthesized by direct iodination of tyrosine. Diiodotyrosine (3,5-diiodotyrosine) is synthesized by directly iodinating tyrosine with iodine in the presence of sodium iodide in aqueous ethylamine, or in a mixture of acetic and hydrochloric acids with the addition of hydrogen peroxide. In pharmaceutical and supplement contexts, DIT has been formulated in oral tablet or capsule forms. It is also a constituent of desiccated thyroid preparations derived from animal thyroid glands, which contain both free and protein-bound iodinated tyrosines alongside the active thyroid hormones. Thyroid hormone preparations belong to two categories: natural hormonal preparations derived from animal thyroid, and synthetic preparations. Natural preparations include desiccated thyroid and thyroglobulin; desiccated thyroid is derived from domesticated animals used for food by humans (either beef or hog thyroid), and thyroglobulin is derived from thyroid glands of the hog.

2. Traditional and Historical Use

2.1 Early Isolation and Recognition in Marine Organisms

The story of diiodotyrosine as a recognized substance begins in the marine natural products tradition. Iodogorgoric acid (3,5-diiodotyrosine) was first isolated over 100 years ago from the marine gorgonian Gorgonia cavolinii, a soft coral. This discovery — occurring in the late 19th to early 20th century — preceded any understanding of its role in thyroid physiology, and was part of a broader observation that marine invertebrates concentrate iodine. Many other early studies identified iodine and bromine in marine organisms, which eventually connected to the developing science of thyroid endocrinology.

2.2 Seaweed and Iodine in Traditional Medical Practice

Long before the biochemistry of DIT was elucidated, populations and practitioners in coastal regions made use of seaweed and marine preparations — unknowingly delivering iodinated compounds including DIT — to treat thyroid-related conditions such as goiter. Oriental Materia Medica gives descriptions of activity of some seaweed: Kunbu, a mixture of the brown algae Laminaria and Ecklonia, was used for liver, stomach, and/or kidney illness; Haizao (Sargassum species) was used for scrofula, goiter, tumor, edema, testicular pain and swelling. These uses represent the traditional application of iodine-rich marine plants in East Asian medicine, with goiter being a prime target.

In the Western tradition, iodine itself (as an element found in abundance in the same marine sources) was recognized as a goiter remedy. The use of iodine to prevent goiter was proposed in 1831 — on the basis of observations in Colombia, South America — and later in 1850 by Chatin, a Parisian pharmacist, botanist, and physician. However, in the early 19th century, iodine was added to food and water after it was suggested as prophylaxis for goiter, but this practice was abandoned until Dr. David Marine's landmark experiment in 1916–1920 where iodide administration to 5,000 schoolgirls in Akron, Ohio, prevented development of endemic goiter.

2.3 Early 20th-Century Pharmaceutical Use of DIT

As thyroid endocrinology advanced in the early 20th century, DIT itself attracted pharmaceutical interest as a specific thyroid modulator. Diiodotyrosine does not possess pronounced hormonal activity; however, it stops production of thyrotropic hormone by the anterior lobe of the hypophysis, which activates thyroid gland activity. It was used for hyperthyroid forms of endemic and sporadic goiters, diffuse toxic goiters, and other illnesses accompanied by thyrotoxicity. This pharmacological application — using DIT as a pituitary TSH suppressor for goiter and hyperthyroidism — was a recognized use in the mid-20th century, particularly in continental European pharmacology, under the trade names ditirin and iodoglobin.

3. Key Constituents, Biochemistry, and Mechanisms of Action

3.1 DIT as a Thyroid Hormone Biosynthetic Intermediate

The primary established biochemical role of DIT is as an obligate intermediate in the synthesis of the thyroid hormones thyroxine (T4) and triiodothyronine (T3). The biosynthetic sequence within the thyroid gland proceeds through four key steps. First, inorganic iodide from circulating blood is actively taken up ("trapped") by the sodium/iodide symporter (NIS). Second, iodide is oxidized by thyroperoxidase (TPO) in the presence of hydrogen peroxide. Third, the activated iodine is incorporated into tyrosine residues of the large precursor glycoprotein thyroglobulin (TG) — a process called organification — generating monoiodotyrosine (MIT) and diiodotyrosine (DIT) residues within the protein. The transported iodide ion becomes covalently attached to the precursor thyroid hormone glycoprotein thyroglobulin at the interface between the apical membrane and the follicular lumen by the enzyme thyroperoxidase (TPO); tyrosine molecules in the thyroglobulin molecule are then iodinated to form monoiodotyrosines (MITs) and diiodotyrosines (DITs). Fourth, an oxidative coupling reaction also catalyzed by TPO joins specific iodotyrosine pairs: the bioactive thyroid hormones L-thyroxine (T4) and triiodothyronine (T3) are formed by the coupling of two DITs or one DIT with one MIT, respectively, by TPO.

In quantitative terms, T4 contains four iodine atoms and is formed by the coupling of two molecules of diiodotyrosine (DIT), while T3 contains three atoms of iodine and is formed by the coupling of one molecule of DIT with one molecule of monoiodotyrosine (MIT). Both hormones are stored in the thyroid colloid as thyroglobulin until proteolytic release and secretion are signaled.

3.2 DIT as a Modulator of Thyroid Peroxidase

Beyond its structural role as a coupling substrate, free (non-protein-bound) DIT has been documented to exert regulatory effects on the enzyme thyroid peroxidase itself. DIT is a precursor in the production of thyroid hormone, and it is also a modulator of the enzyme thyroid peroxidase (which is involved in the production of thyroid hormones).

Research published in the European Journal of Biochemistry in 1975 by Dème, Fimiani, Pommier, and Nunez characterised these effects in biochemical detail. Free diiodotyrosine exerts two opposite effects on the reactions catalyzed by thyroid peroxidase: inhibition of thyroglobulin iodination was observed when free diiodotyrosine concentration was higher than 5 µM; this inhibition was competitive, suggesting that free diiodotyrosine interacts with the substrate site(s) of thyroid peroxidase. Free diiodotyrosine also competitively inhibited iodide peroxidation to I₂. Conversely, at very low concentrations, DIT exerts a stimulatory effect on hormone synthesis: free diiodotyrosine, when present at a very low concentration of 0.05 µM, exerts a stimulatory effect on thyroid hormone synthesis, and the relationship between diiodotyrosine concentration and thyroid hormone synthesis gives an S-shaped curve, suggesting that free diiodotyrosine acts as a regulatory ligand for thyroid peroxidase.

A further mechanism was described in a 1981 European Journal of Biochemistry study by Virion et al., which demonstrated that free DIT participates directly in the coupling reaction that forms T3 and T4: the respective role of iodide and of free diiodotyrosine on thyroid hormone synthesis (coupling reaction) was analysed under a variety of enzymatic and non-enzymatic conditions; free diiodotyrosine stimulated the coupling reaction not only with thyroid peroxidase but also with lactoperoxidase and horseradish peroxidase. Preformed iodotyrosine residues were efficiently coupled with thyroid peroxidase only in the presence of either iodide or free diiodotyrosine, alone or combined. Additionally, thyroid peroxidase catalyzes the two-electron oxidation of tyrosine and monoiodotyrosine, and the one-electron oxidation of diiodotyrosine; this difference in oxidation is also observed in the reaction of thyroid peroxidase with differently iodinated thyroglobulins, supporting the hypothesis that the increase in the diiodotyrosine residue in thyroglobulin inhibits further iodination by switching the catalytic cycle to oxidative coupling to form thyroid hormones.

3.3 TSH-Suppressive Activity

At the level of the pituitary–thyroid axis, DIT has been identified as an inhibitor of thyrotropin (TSH) secretion from the anterior pituitary. Diiodotyrosine does not possess pronounced hormonal activity; however, it stops production of thyrotropic hormone by the anterior lobe of the hypophysis, which activates thyroid gland activity. This TSH-suppressive property underlies its historical use in goiter and hyperthyroid states.

3.4 Iodide Recycling via Iodotyrosine Deiodinase (IYD)

DIT is a primary substrate of the enzyme iodotyrosine deiodinase (IYD, also called iodotyrosine dehalogenase 1, encoded by the gene DEHAL1/IYD). This enzyme is essential for conserving iodide within the body. Daily ingestion of iodide alone is not adequate to sustain production of the thyroid hormones; proper maintenance of iodide in vivo also requires its active transport into the thyroid and its salvage from mono- and diiodotyrosine that are formed in excess during hormone biosynthesis. The enzyme iodotyrosine deiodinase responsible for this salvage is unusual in its ability to catalyze a reductive dehalogenation reaction dependent on a flavin cofactor, FMN.

Iodotyrosine deiodinase facilitates iodide salvage in the thyroid by catalyzing deiodination of mono- and diiodotyrosine; iodide is an important micronutrient in the biosynthesis of thyroid hormone, creating a cycle of iodide use. Iodotyrosine deiodinase is located on the apical plasma membrane of the thyroid colloid, where mono- and diiodotyrosine are produced from the breakdown of thyroglobulin. Without iodotyrosine deiodinase activity, the iodide would be excreted with the amino acid tyrosine and thyroid hormone biosynthesis would be reduced. The enzyme acts exclusively on MIT and DIT: IYD is distinct from other iodotyronine deiodinases that catalyze the deiodination of thyroid hormones (D1, D2, D3) because IYD acts on only MIT and DIT but not T4 and T3.

The IYD enzyme is highly conserved across evolution. The equivalently large drifts in IYD sequence between the three branches of life suggest that this enzyme may have appeared very early in evolution when iodinated compounds might have been common; contrary to initial expectations, IYD did not emerge with the advent of thyroid hormones but instead was co-opted from another function to salvage iodide from iodotyrosines for thyroxine biosynthesis in Chordata.

4. Scientific Evidence by Area of Application

4.1 Thyroid Hormone Synthesis and Endocrine Physiology

The role of DIT in thyroid hormone biosynthesis is established mechanistic science, not primarily derived from clinical supplementation trials but from decades of biochemical, molecular, and physiological research. The position of DIT as the direct structural precursor to both T3 and T4 within the thyroid follicular apparatus is a textbook fact of endocrinology supported by a vast body of molecular biology and protein structural studies. Thyroid hormones are essential regulators of metabolism, development, and growth; they are formed from pairs of iodinated tyrosine residues within the precursor thyroglobulin (TG), a 660-kDa homodimer of the thyroid gland, by an oxidative coupling reaction. Recent cryo-electron microscopy work has allowed visualization of DIT coupling sites within native thyroglobulin structure at atomic resolution. A ~3.3-Å cryo-EM structure of native bovine thyroglobulin with nascent thyroid hormone formed at one of the predicted hormonogenic sites has been reported, providing insight into mechanisms underlying thyroid hormone formation and stabilization.

Evidence strength: The mechanistic and structural biochemistry of DIT in thyroid hormone biosynthesis is supported by very strong, replicated, multi-method research including biochemical kinetics, genetics, and structural biology. This is not supplementation evidence per se but foundational biological science.

4.2 Goiter and Hyperthyroidism (Historical Clinical Use)

As a drug entity (under names such as ditirin, iodoglobin, Agontan), DIT was employed clinically — chiefly in the mid-20th century — for goiter and hyperthyroid states, primarily by exploiting its TSH-suppressive properties. Diiodotyrosine does not possess pronounced hormonal activity; however, it stops production of thyrotropic hormone by the anterior lobe of the hypophysis, which activates thyroid gland activity, and was used for hyperthyroid forms of endemic and sporadic goiters, diffuse toxic goiters, and other illnesses accompanied by thyrotoxicity.

Evidence strength: The clinical evidence base from these older applications consists largely of historical case series and observational data from the pre-randomized-controlled-trial era. No modern placebo-controlled clinical trials of DIT as a standalone supplement in goiter or hyperthyroidism have been identified in the peer-reviewed literature search. This area is therefore classified as having historically documented clinical use with insufficient modern controlled evidence.

4.3 APOBEC3B Inhibition and Cancer Biology

A more recent and significant scientific discovery involves the potential of 3,5-diiodotyrosine in oncology. A 2022 study published in Journal for ImmunoTherapy of Cancer (Chen et al., PMID 36323433) investigated whether natural products could inhibit the cytidine deaminase APOBEC3B, a mutation driver implicated in multiple cancers. The cytidine deaminase APOBEC3B-correlated somatic mutations were widely observed in a variety of cancers, and its overexpression indicated poor survival; 3,5-diiodotyrosine (SMC247), described as a source of kelp iodine, could strongly bind APOBEC3B (K_D = 65 nM) and effectively inhibit its deaminase activity (IC₅₀ = 1.69 µM).

The study employed computer-aided screening, cell-line work, and two spontaneous mouse cancer models (esophageal and colon cancer). 4-nitroquinoline-1-oxide (4-NQO)-induced spontaneous esophageal squamous cell carcinoma (ESCC) and azoxymethane/dextran sulfate sodium (AOM/DSS)-induced spontaneous colon cancer mouse models were conducted to investigate the influences of APOBEC3B inhibitor on the prevention of somatic mutation accumulation and cancer progression. Both low and high doses of 3,5-diiodotyrosine could significantly prolong the overall survival of mice and slow down the loss trend of body weight. Additional immunological findings were noted: 3,5-diiodotyrosine could reduce colitis, increase the proportion and function of T lymphocytes via IL-15 in the tumor microenvironment, and synergistic cancer prevention effects were observed when 3,5-diiodotyrosine was combined with PD-1/PD-L1 blockade.

The authors themselves characterized this as a proof-of-concept study: this is the first proof-of-concept study to elucidate that the natural product 3,5-diiodotyrosine could prevent somatic mutation accumulation and cancer progression through inhibiting the enzymatic activity of APOBEC3B.

Evidence strength: Preliminary, preclinical only. All cancer-related findings to date are from in vitro binding assays and mouse models. No human clinical data exist. These results are hypothesis-generating and require substantial further investigation before any clinical conclusions can be drawn.

4.4 Iodide Homeostasis and Iodine Deficiency

The physiological relationship between DIT metabolism and iodine homeostasis is well documented. Because DIT represents a major endogenous reservoir of organified iodide, disruption of its normal deiodination leads directly to iodine wasting and hypothyroidism. Failure to deiodinate thyroid monoiodotyrosine (MIT) and diiodotyrosine (DIT) as they are released from thyroglobulin leads to severe iodine wastage, because the non-deiodinated MIT and DIT leak out of the thyroid and are excreted in urine; the patients originally described were hypothyroid, with goiters presenting at birth or shortly thereafter.

The measurable presence of DIT in serum and urine has also been proposed as a biomarker. Urinary monoiodotyrosine (MIT) and diiodotyrosine (DIT) excretion can be used to delineate the phenotype of iodotyrosine deiodinase defects. These findings are particularly relevant to understanding the pathophysiology of iodine metabolism disorders rather than to supplementation efficacy.

4.5 Metabolic Regulation

Because DIT is the direct precursor of thyroid hormones — which are master regulators of basal metabolic rate, thermogenesis, cardiovascular function, growth, and neurological development — its role in metabolic physiology is indirectly vast. T3 (tri-iodothyronine) and T4 (tetra-iodothyronine, thyroxine) are essential regulators of metabolism, development, and growth in all vertebrates and some invertebrates. However, no direct human clinical evidence currently demonstrates that exogenous DIT supplementation meaningfully alters thyroid hormone output or metabolic parameters in healthy individuals with normal thyroid function and iodine sufficiency.

5. Body Systems and Health Areas of Association

Endocrine/Thyroid system: DIT is most closely and directly associated with the thyroid gland. The thyroid gland produces two hormones, thyroxine (T4) and triiodothyronine (T3); four steps are involved in the synthesis of these hormones, including iodide trapping, oxidation, organification (iodine added to tyrosine to produce monoiodotyrosine and diiodotyrosine), and coupling (one monoiodotyrosine is coupled with one diiodotyrosine to yield T3, and two diiodotyrosines are coupled to yield T4).
Hypothalamic–pituitary axis: DIT's established pharmacological ability to suppress TSH secretion from the anterior pituitary links it directly to the HPT (hypothalamic–pituitary–thyroid) regulatory axis. It stops production of thyrotropic hormone by the anterior lobe of the hypophysis, which activates thyroid gland activity.
Metabolic regulation: Through its role in thyroid hormone biosynthesis, DIT is indirectly associated with basal metabolic rate, thermogenesis, cardiac output, lipid metabolism, and body weight regulation — all functions regulated by the T3 and T4 it helps produce. Thyroid hormone is important for growth, development, and the maintenance of homeostasis in many organisms including humans.
Oncological (investigational): As an APOBEC3B inhibitor in preclinical models, DIT is now linked investigationally to mutation-driven cancer biology. 3,5-diiodotyrosine could reduce colitis and increase the infiltration and function of T lymphocytes via IL-15 in the tumor microenvironment; 3,5-diiodotyrosine combined with PD-1/PD-L1 blockade could elicit synergistic cancer prevention effects, indicating a novel strategy for both preventing somatic mutation accumulation and the immune-suppressive microenvironment.
Neurological development: Through its indispensable role in thyroid hormone production, DIT is intrinsically linked to brain development and cognitive function. The consequences of insufficient thyroid hormone — themselves linked to failures in DIT production or metabolism — include cretinism and intellectual impairment. Iodine deficiency remained a significant public health issue throughout the 20th century; UNICEF has called iodine deficiency the greatest preventable cause of cognitive deficits.
Iodide homeostasis: The iodide recycling enzyme iodotyrosine deiodinase (IYD) is an important molecular mechanism related to thyroid function; this highly conserved enzyme plays an essential role in maintaining adequate levels of free iodide for thyroid hormone synthesis, and thyroid disruption following in vivo IYD inhibition has been documented in mammalian and amphibian models.

6. Dosage Forms and Reported Dosages

In the older pharmaceutical literature and in early patents, DIT was administered orally. A US patent (US 5,200,428) for TSH suppression and goiter treatment specifically states: it was unexpectedly determined that 3,5-diiodo-L-thyronine, in a long-term application taking weeks, in a highly significant manner reduces the TSH level and hence is suitable as a highly efficient agent for the treatment of struma (goiter); one dosage unit should contain from 1 to 5 mg of 3,5-diiodo-L-thyronine. It should be noted that this patent refers to 3,5-diiodo-L-thyronine (a thyronine derivative), which, while structurally related, is distinct from 3,5-diiodotyrosine (DIT) itself; DIT is the tyrosine-based precursor, whereas 3,5-diiodothyronine is a downstream metabolite. This distinction is important and is frequently conflated in older sources.

For the research compound 3,5-diiodotyrosine in the 2022 cancer biology study, both "low and high doses" were tested in mouse models, with the referenced molecule having a molecular weight of 432.98 g/mol. Specific human dosages for DIT as a dietary supplement have not been established in peer-reviewed clinical trials identified in this review. In in vitro studies, inhibition of thyroglobulin iodination by free DIT was observed at concentrations above 5 µM, while stimulation of hormone synthesis was documented at 0.05 µM, and maximal stimulation of the coupling reaction was obtained at approximately 0.5 µM.

7. Safety Considerations and Interactions

7.1 IYD Deficiency: The Consequence of Defective DIT Deiodination

The most rigorously documented safety-relevant physiology surrounding DIT relates not to exogenous intake but to the consequences when the body fails to metabolize it normally. Iodotyrosine deiodinase is a thyroidal enzyme that deiodinates mono- and diiodotyrosines (MIT, DIT) and recycles iodine for the efficient synthesis of thyroid hormone; failure of this enzyme leads to hypothyroidism, goiter and mental retardation — a clinical phenotype described since the 1950s — whose diagnostic hallmark is the elevation of iodotyrosines in serum and urine.

The molecular basis of this condition was unraveled with the cloning of the DEHAL1 gene. Mutations of the DEHAL1 gene have been identified in patients with congenital hypothyroidism from three different families; the phenotype is variable and includes goiter, mental retardation, or normal mental development despite delayed thyroid hormone substitution. A landmark clinical genetics paper published in the New England Journal of Medicine (PMID linked to Moreno et al.) confirmed that elevated serum diiodotyrosine is a hallmark finding in affected patients. One patient's serum diiodotyrosine level was elevated; patients for screening were selected for DEHAL1 mutations on the basis of hypothyroidism and goiter with additional features consistent with iodotyrosine deiodinase deficiency, including elevated serum diiodotyrosine levels.

The current clinical picture of mutations in DEHAL1 mostly recapitulates the "classical" phenotype including psychomotor deficits; this is probably due to the lack of expression of the disease at the beginning of life, which causes ITDD being undetected in current screening programs for congenital hypothyroidism. This feature calls for efforts to improve the preclinical detection of iodotyrosine deiodinase deficiency in the neonatal period.

7.2 Iodine Load and Thyroid Disruption

Because DIT carries two iodine atoms per molecule, administration of exogenous DIT constitutes an organic iodine load. Excessive iodide intake is known to have biphasic effects on thyroid function — initially inhibiting hormone synthesis through the Wolff–Chaikoff effect and, with prolonged high intake, potentially triggering either hypothyroidism or hyperthyroidism depending on the individual's underlying thyroid status. Research has documented that excessive iodide inhibits DIT synthesis in the thyroid itself: studies referenced in the historical thyroid pharmacology literature include work on "the inhibitory action of excessive iodide upon the synthesis of diiodotyrosine and of thyroxine in the thyroid gland of the normal rat." The iodide recycling enzyme IYD is a molecular mechanism through which environmental chemicals can potentially cause thyroid disruption; this highly conserved enzyme plays an essential role in maintaining adequate levels of free iodide for thyroid hormone synthesis, and thyroid disruption following in vivo IYD inhibition has been documented in mammalian and amphibian models.

7.3 Interactions with Thyroid-Active Drugs and Compounds

Because DIT directly modulates thyroid peroxidase — the central enzyme of thyroid hormone synthesis — it has the theoretical potential to interact with any agent that also acts on this pathway. Drugs that inhibit TPO include the thionamides (propylthiouracil, methimazole) used to treat hyperthyroidism. The reaction of iodide oxidation catalyzed by peroxidase is inhibited by thyrotoxic agents such as the thiouracils or thioureas and stimulated by TSH; propylthiouracil is commonly used in the treatment of hyperthyroidism. Co-administration of high-dose exogenous DIT with such agents has not been studied and could produce additive or antagonistic effects on thyroid hormone synthesis, though no direct human data are available.

Dietary flavonoids represent another class of compounds that interact with thyroid peroxidase. Quercetin is among the most powerful of the flavonoid-based inhibitors of TPO, the irreversible inhibition resulting from covalent attachment of an oxidized form of quercetin generated by TPO to TPO itself. Individuals who consume high quantities of flavonoid-containing foods or supplements alongside iodinated compounds may therefore experience altered thyroid peroxidase activity, though the clinical significance in humans at normal dietary intakes remains unclear.

7.4 Potential Iodine Excess from High-DIT Sources (Kelp/Seaweed)

Natural sources of DIT — particularly kelp and brown seaweeds — are associated with documented risks of iodine excess when consumed in large quantities. The iodine content in one portion of wholefood macroalgae products ranged from 128 to 62,400 µg; in macroalgae-containing foods, it ranged from 30 to 25,300 µg per portion, and in supplements from 5 to 5,600 µg per daily dose. The species with the highest iodine content included oarweed, sugar kelp and kombu. For 54 products analyzed, the intake of one portion or dose would exceed the tolerable upper intake level (UL) for iodine. Individuals using kelp-derived supplements as a source of DIT therefore face non-trivial iodine excess risk from the associated inorganic and organic iodine load.

7.5 Absence of Established Safety Data for Isolated DIT Supplementation

No systematic safety studies, toxicology data in humans, or pharmacovigilance data on isolated DIT as a dietary supplement have been identified in peer-reviewed literature or regulatory databases in the course of this review. DIT's scientific validation largely stems from its established biochemical role in thyroid hormone synthesis rather than direct clinical evidence as a supplement ingredient. The absence of controlled clinical trial data means that any statements about safety, tolerability, drug interactions, or contraindications specific to supplemental DIT must be considered speculative in the current state of evidence.

8. Evidence Summary and Research Gaps

The scientific standing of diiodotyrosine is unusual among dietary supplement ingredients: its endogenous biochemical role — as the obligate precursor to thyroid hormones and as a regulator of thyroid peroxidase — is among the most thoroughly characterized in all of endocrinology. Conversely, its standing as an exogenous dietary supplement ingredient is remarkably underdeveloped, with no placebo-controlled human clinical trials identified specifically investigating DIT supplementation as an intervention.

The most novel and potentially significant frontier of DIT research involves its identification as an APOBEC3B inhibitor. The cytidine deaminase APOBEC3B-correlated somatic mutations were widely observed in a variety of cancers, and its overexpression indicated poor survival. The 2022 proof-of-concept study is the first of its kind and must be regarded as hypothesis-generating preclinical work only.

Key research gaps include: (1) human clinical trials of oral DIT supplementation with thyroid hormone and TSH endpoints; (2) bioavailability studies establishing the fraction of ingested DIT that reaches systemic circulation versus being hydrolyzed in the gut; (3) dose-finding and safety studies in healthy volunteers; (4) clinical translation of the APOBEC3B inhibitor findings; and (5) comparative studies against established iodine supplementation forms. Until such data exist, DIT's status as a dietary supplement ingredient should be understood in the context of its established endogenous biochemistry rather than a robust supplementation evidence base.

References

Health Conditions

Health conditions that Diiodotyrosine may help support.

Thyroid HealthScientific
Diiodotyrosine (DIT) is an endogenous intermediate in thyroid hormone biosynthesis, formed when two iodine atoms are added to tyrosine residues on thyroglobulin. Two DIT molecules couple to form thyroxine (T4). It is included in some thyroid support supplement formulas and has been used clinically as a nutritional adjunct for thyroid support.

Body Systems

Body systems that Diiodotyrosine may help support.

No body systems available.